arrow
H

Harvey D. White

university of auckland
H指数:138
被引数:12.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lipoprotein(a), smoking, and diabetes are additive but not interactive risk factors for major adverse cardiovascular events after acute coronary syndrome

脂蛋白(a)、吸烟和糖尿病是急性冠脉综合征后主要不良心血管事件的相加但非交互风险因素

2026-08-310
OAAI
Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations (vol 32, pg 287, 2023)
2026-01-010
PRE
Future myocardial infarction after an acute coronary syndrome and pharmacogenetic response to dalcetrapib

急性冠脉综合征后未来心肌梗死及dalcetrapib的药代遗传学反应

2025-11-010
PRE
Association Between Electrocardiographic Changes and Myocardial Injury or Death after Cardiac Surgery

心电图变化与心脏手术后心肌损伤或死亡之间的关系

2025-09-260
PREAI
Use of coronary artery bypass graft surgery and percutaneous coronary intervention and associated outcomes in the ISCHEMIA trial

冠状动脉旁路移植术和经皮冠状动脉介入治疗的使用及其在ISCHEMIA试验中的相关结局

2025-05-200
PRE
Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial

与脂蛋白(a)、低密度脂蛋白胆固醇及其在Alirocumab作用下变化相关的糖尿病发生风险:ODYSSEY OUTCOMES随机试验的事后分析

2025-02-060
PRE
Effect of Four Hemoglobin Transfusion Threshold Strategies in Patients With Acute Myocardial Infarction and Anemia

四种血红蛋白输血阈值策略对急性心肌梗死合并贫血患者的影响

2024-11-011
PRE
International Variation in Health Status Benefits in Patients Undergoing Initial Invasive Versus Conservative Management for Chronic Coronary Disease: Insights From the ISCHEMIA Trial
2024-10-010
PRE
Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial

根据基线LDL-胆固醇水平输注载脂蛋白A-I和急性心肌梗死的心血管结局: AEGIS-II试验

2024-09-021
PRE
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

PCSK9抑制剂alirocumab的安全性: 来自47名296患者的见解-观察年

2024-04-206
OAAI